{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:42:16Z","timestamp":1792788136153,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004329","name":"The Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["Young Researcher Programme"],"award-info":[{"award-number":["Young Researcher Programme"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"The Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["J7-60125"],"award-info":[{"award-number":["J7-60125"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"The Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P3-0314"],"award-info":[{"award-number":["P3-0314"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ljubljana University Medical Centre","award":["Tertiary Project 20240076"],"award-info":[{"award-number":["Tertiary Project 20240076"]}],"id":[{"id":"https:\/\/ror.org\/01nr6fy72","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-026-03867-x","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:24:14Z","timestamp":1784615054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dysregulated IL-6 pathway activity in idiopathic inflammatory myopathies"],"prefix":"10.1186","volume":"28","author":[{"given":"Anja","family":"Srp\u010di\u010d","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicita","family":"Urzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manca","family":"Ogri\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojca","family":"Frank Bertoncelj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u0161a","family":"\u010cu\u010dnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polonca","family":"Mali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergej","family":"Pirkmajer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Lakota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Perdan Pirkmajer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"issue":"2","key":"3867_CR1","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/S2665-9913(23)00322-3","volume":"6","author":"CM Connolly","year":"2024","unstructured":"Connolly CM, Gupta L, Fujimoto M, Machado PM, Paik JJ. Idiopathic inflammatory myopathies: current insights and future frontiers. Lancet Rheumatol. 2024;6(2):e115\u201327.","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"3867_CR2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/25785826.2024.2413604","volume":"48","author":"M Ogawa-Momohara","year":"2025","unstructured":"Ogawa-Momohara M, Muro Y. Myositis-specific and myositis-associated autoantibodies: their clinical characteristics and potential pathogenic roles. Immunol Med. 2025;48(2):104\u201316.","journal-title":"Immunol Med"},{"issue":"5","key":"3867_CR3","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","volume":"61","author":"AGS Oldroyd","year":"2022","unstructured":"Oldroyd AGS, Lilleker JB, Amin T, Aragon O, Bechman K, Cuthbert V, et al. British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology (Oxford). 2022;61(5):1760\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"3867_CR4","doi-asserted-by":"crossref","first-page":"105932","DOI":"10.1016\/j.jbspin.2025.105932","volume":"92","author":"R Campanilho-Marques","year":"2025","unstructured":"Campanilho-Marques R, Fonseca JE, Machado PM. Treatment of idiopathic inflammatory myopathies. Joint Bone Spine. 2025;92(6):105932.","journal-title":"Joint Bone Spine"},{"issue":"3","key":"3867_CR5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/08916930600622256","volume":"39","author":"S Salomonsson","year":"2006","unstructured":"Salomonsson S, Lundberg IE. Cytokines in idiopathic inflammatory myopathies. Autoimmunity. 2006;39(3):177\u201390.","journal-title":"Autoimmunity"},{"issue":"10","key":"3867_CR6","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1093\/rheumatology\/keq151","volume":"49","author":"P Szodoray","year":"2010","unstructured":"Szodoray P, Alex P, Knowlton N, Centola M, Dozmorov I, Csipo I, et al. Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand. Rheumatology (Oxford). 2010;49(10):1867\u201377.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"3867_CR7","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/mus.10462","volume":"28","author":"D Figarella-Branger","year":"2003","unstructured":"Figarella-Branger D, Civatte M, Bartoli C, Pellissier JF. Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve. 2003;28(6):659\u201382.","journal-title":"Muscle Nerve"},{"issue":"3","key":"3867_CR8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/cei.12445","volume":"178","author":"EM Moran","year":"2014","unstructured":"Moran EM, Mastaglia FL. Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications. Clin Exp Immunol. 2014;178(3):405\u201315.","journal-title":"Clin Exp Immunol"},{"key":"3867_CR9","doi-asserted-by":"crossref","first-page":"103522","DOI":"10.1016\/j.jaut.2025.103522","volume":"158","author":"C Leijding","year":"2026","unstructured":"Leijding C, Gastaldello S, Schiffer T, Kaewin S, Andreasson KM, Zhong Y, et al. Sera from patients with dermatomyositis and antisynthetase syndrome mediate muscle weakness, impair mitochondrial respiration and induce local cytokine production in muscle tissue. J Autoimmun. 2026;158:103522.","journal-title":"J Autoimmun"},{"key":"3867_CR10","first-page":"717808","volume":"2013","author":"M Yang","year":"2013","unstructured":"Yang M, Cen X, Xie Q, Zuo C, Shi G, Yin G. Serum interleukin-6 expression level and its clinical significance in patients with dermatomyositis. Clin Dev Immunol. 2013;2013:717808.","journal-title":"Clin Dev Immunol"},{"issue":"5","key":"3867_CR11","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40744-024-00699-6","volume":"11","author":"Q Zheng","year":"2024","unstructured":"Zheng Q, Wang Z, Tan Y, Zhu K, Lu M. Over Activation of IL-6\/STAT3 Signaling Pathway in Juvenile Dermatomyositis. Rheumatol Ther. 2024;11(5):1255\u201369.","journal-title":"Rheumatol Ther"},{"issue":"12","key":"3867_CR12","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","volume":"53","author":"T Gono","year":"2014","unstructured":"Gono T, Kaneko H, Kawaguchi Y, Hanaoka M, Kataoka S, Kuwana M, et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology (Oxford). 2014;53(12):2196\u2013203.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"3867_CR13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13075-024-03415-5","volume":"26","author":"Y Niu","year":"2024","unstructured":"Niu Y, Liu S, Qiu Q, Fu D, Xiao Y, Liang L, et al. Increased serum level of IL-6 predicts poor prognosis in anti-MDA5-positive dermatomyositis with rapidly progressive interstitial lung disease. Arthritis Res Ther. 2024;26(1):184.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"3867_CR14","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","volume":"40","author":"A Kimura","year":"2010","unstructured":"Kimura A, Kishimoto T. IL-6: regulator of Treg\/Th17 balance. Eur J Immunol. 2010;40(7):1830\u20135.","journal-title":"Eur J Immunol"},{"issue":"17","key":"3867_CR15","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1111\/febs.12338","volume":"280","author":"P Munoz-Canoves","year":"2013","unstructured":"Munoz-Canoves P, Scheele C, Pedersen BK, Serrano AL. Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword? FEBS J. 2013;280(17):4131\u201348.","journal-title":"FEBS J"},{"issue":"4","key":"3867_CR16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/SPC.0000000000000091","volume":"8","author":"AA Narsale","year":"2014","unstructured":"Narsale AA, Carson JA. Role of interleukin-6 in cachexia: therapeutic implications. Curr Opin Support Palliat Care. 2014;8(4):321\u20137.","journal-title":"Curr Opin Support Palliat Care"},{"issue":"1","key":"3867_CR17","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1172\/JCI118398","volume":"97","author":"T Tsujinaka","year":"1996","unstructured":"Tsujinaka T, Fujita J, Ebisui C, Yano M, Kominami E, Suzuki K, et al. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest. 1996;97(1):244\u20139.","journal-title":"J Clin Invest"},{"issue":"8","key":"3867_CR18","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/art.24689","volume":"60","author":"N Okiyama","year":"2009","unstructured":"Okiyama N, Sugihara T, Iwakura Y, Yokozeki H, Miyasaka N, Kohsaka H. Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum. 2009;60(8):2505\u201312.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"3867_CR19","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s42255-022-00538-4","volume":"4","author":"TM Kistner","year":"2022","unstructured":"Kistner TM, Pedersen BK, Lieberman DE. Interleukin 6 as an energy allocator in muscle tissue. Nat Metab. 2022;4(2):170\u20139.","journal-title":"Nat Metab"},{"issue":"Pt 1","key":"3867_CR20","first-page":"1","volume":"374","author":"PC Heinrich","year":"2003","unstructured":"Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374(Pt 1):1\u201320.","journal-title":"Biochem J"},{"issue":"Pt 2","key":"3867_CR21","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1042\/bj3000281","volume":"300","author":"S Rose-John","year":"1994","unstructured":"Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J. 1994;300(Pt 2):281\u201390.","journal-title":"Biochem J"},{"key":"3867_CR22","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2147\/ITT.S485684","volume":"14","author":"T Schumertl","year":"2025","unstructured":"Schumertl T, Lokau J, Garbers C. IL-6 Signaling in Immunopathology: From Basic Biology to Selective Therapeutic Intervention. Immunotargets Ther. 2025;14:681\u201395.","journal-title":"Immunotargets Ther"},{"key":"3867_CR23","doi-asserted-by":"crossref","unstructured":"Rose-John S, Jenkins BJ, Garbers C, Moll JM, Scheller J. Targeting IL-6 trans-signalling: past, present and future prospects. Nat Rev Immunol. 2023;23(10):666\u201381.","DOI":"10.1038\/s41577-023-00856-y"},{"issue":"1","key":"3867_CR24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaci.2021.11.016","volume":"149","author":"A Cheng","year":"2022","unstructured":"Cheng A, Holland SM. Anticytokine autoantibodies: Autoimmunity trespassing on antimicrobial immunity. J Allergy Clin Immunol. 2022;149(1):24\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"3867_CR25","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.febslet.2007.04.029","volume":"581","author":"M Watanabe","year":"2007","unstructured":"Watanabe M, Uchida K, Nakagaki K, Kanazawa H, Trapnell BC, Hoshino Y, et al. Anti-cytokine autoantibodies are ubiquitous in healthy individuals. FEBS Lett. 2007;581(10):2017\u201321.","journal-title":"FEBS Lett"},{"issue":"3","key":"3867_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41577-023-00933-2","volume":"24","author":"A Cheng","year":"2024","unstructured":"Cheng A, Holland SM. Anti-cytokine autoantibodies: mechanistic insights and disease associations. Nat Rev Immunol. 2024;24(3):161\u201377.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"3867_CR27","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1038\/s41598-023-28838-z","volume":"13","author":"M Casal-Dominguez","year":"2023","unstructured":"Casal-Dominguez M, Pinal-Fernandez I, Pak K, Munoz-Braceras S, Milisenda JC, Torres-Ruiz J, et al. Coordinated local RNA overexpression of complement induced by interferon gamma in myositis. Sci Rep. 2023;13(1):2038.","journal-title":"Sci Rep"},{"issue":"3","key":"3867_CR28","first-page":"100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innov (Camb). 2021;2(3):100141.","journal-title":"Innov (Camb)"},{"key":"3867_CR29","unstructured":"Yu G. enrichplot. Visualization of Functional Enrichment Results. R package version 1.18.0.2022."},{"key":"3867_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"3867_CR31","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1038\/s41467-024-49460-1","volume":"15","author":"C Abad","year":"2024","unstructured":"Abad C, Pinal-Fernandez I, Guillou C, Bourdenet G, Drouot L, Cosette P, et al. IFNgamma causes mitochondrial dysfunction and oxidative stress in myositis. Nat Commun. 2024;15(1):5403.","journal-title":"Nat Commun"},{"issue":"10","key":"3867_CR32","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/acr2.11724","volume":"6","author":"R Najjar","year":"2024","unstructured":"Najjar R, Alessi H, Pinal-Fernandez I, Mammen AL, Mustelin T. Distinct Transcript-Level Expression Profiles and Unique Alternative Splicing in Inflammatory Myopathies. ACR Open Rheumatol. 2024;6(10):690\u20139.","journal-title":"ACR Open Rheumatol"},{"issue":"1\u20132","key":"3867_CR33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jim.2012.09.008","volume":"387","author":"G Almanzar","year":"2013","unstructured":"Almanzar G, Ottensmeier B, Liese J, Prelog M. Assessment of IgG avidity against pertussis toxin and filamentous hemagglutinin via an adapted enzyme-linked immunosorbent assay (ELISA) using ammonium thiocyanate. J Immunol Methods. 2013;387(1\u20132):36\u201342.","journal-title":"J Immunol Methods"},{"key":"3867_CR34","doi-asserted-by":"crossref","unstructured":"Chatzis D, Banos A, Fanouriakis A, Karampitsakos T, Tzilas V. Rituximab in Connective Tissue Disease-Associated Interstitial Lung Disease: From Immunopathogenesis to Therapeutic Implications. Int J Mol Sci. 2025;27(1):46.","DOI":"10.3390\/ijms27010046"},{"key":"3867_CR35","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/1471-2474-15-178","volume":"15","author":"H Marco","year":"2014","unstructured":"Marco H, Smith RM, Jones RB, Guerry MJ, Catapano F, Burns S, et al. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord. 2014;15:178.","journal-title":"BMC Musculoskelet Disord"},{"key":"3867_CR36","doi-asserted-by":"crossref","unstructured":"Knight V, Merkel PA, O\u2019Sullivan MD. Anticytokine Autoantibodies: Association with Infection and Immune Dysregulation. Antibodies (Basel). 2016;5(1):3.","DOI":"10.3390\/antib5010003"},{"issue":"8","key":"3867_CR37","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/art.11181","volume":"48","author":"G Cambridge","year":"2003","unstructured":"Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 2003;48(8):2146\u201354.","journal-title":"Arthritis Rheum"},{"issue":"1 Pt 1","key":"3867_CR38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1078-0432.CCR-1160-3","volume":"10","author":"R Hassan","year":"2004","unstructured":"Hassan R, Williams-Gould J, Watson T, Pai-Scherf L, Pastan I. Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1. Clin Cancer Res. 2004;10(1 Pt 1):16\u20138.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3867_CR39","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s11926-023-01105-w","volume":"25","author":"PC Gandiga","year":"2023","unstructured":"Gandiga PC, Ghetie D, Anderson E, Aggrawal R. Intravenous Immunoglobulin in Idiopathic Inflammatory Myopathies: a Practical Guide for Clinical Use. Curr Rheumatol Rep. 2023;25(8):152\u201368.","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"3867_CR40","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1084\/jem.189.3.599","volume":"189","author":"SA Jones","year":"1999","unstructured":"Jones SA, Novick D, Horiuchi S, Yamamoto N, Szalai AJ, Fuller GM. C-reactive protein: a physiological activator of interleukin 6 receptor shedding. J Exp Med. 1999;189(3):599\u2013604.","journal-title":"J Exp Med"},{"issue":"1","key":"3867_CR41","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/art.20727","volume":"52","author":"N Franchimont","year":"2005","unstructured":"Franchimont N, Lambert C, Huynen P, Ribbens C, Relic B, Chariot A, et al. Interleukin-6 receptor shedding is enhanced by interleukin-1beta and tumor necrosis factor alpha and is partially mediated by tumor necrosis factor alpha-converting enzyme in osteoblast-like cells. Arthritis Rheum. 2005;52(1):84\u201393.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"3867_CR42","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.7150\/ijbs.4989","volume":"8","author":"S Rose-John","year":"2012","unstructured":"Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012;8(9):1237\u201347.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"3867_CR43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1096\/fj.99-1003rev","volume":"15","author":"SA Jones","year":"2001","unstructured":"Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J. 2001;15(1):43\u201358.","journal-title":"FASEB J"},{"issue":"2","key":"3867_CR44","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/rheumatology\/keae118","volume":"64","author":"X Ma","year":"2025","unstructured":"Ma X, Gao HJ, Ge HZ, Zhang Q, Bu BT. Interleukin-6 trans-signalling regulates monocyte chemoattractant protein-1 production in immune-mediated necrotizing myopathy. Rheumatology (Oxford). 2025;64(2):849\u201359.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"3867_CR45","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/npr2.12100","volume":"40","author":"K Yamasaki","year":"2020","unstructured":"Yamasaki K, Hasegawa T, Takeda M. Serum level of soluble interleukin 6 receptor is a useful biomarker for identification of treatment-resistant major depressive disorder. Neuropsychopharmacol Rep. 2020;40(2):130\u20137.","journal-title":"Neuropsychopharmacol Rep"},{"issue":"6","key":"3867_CR46","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1365-3083.1991.tb02552.x","volume":"33","author":"MB Hansen","year":"1991","unstructured":"Hansen MB, Svenson M, Diamant M, Bendtzen K. Anti-interleukin-6 antibodies in normal human serum. Scand J Immunol. 1991;33(6):777\u201381.","journal-title":"Scand J Immunol"},{"issue":"11","key":"3867_CR47","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1002\/eji.200425268","volume":"34","author":"P Galle","year":"2004","unstructured":"Galle P, Svenson M, Bendtzen K, Hansen MB. High levels of neutralizing IL-6 autoantibodies in 0.1% of apparently healthy blood donors. Eur J Immunol. 2004;34(11):3267\u201375.","journal-title":"Eur J Immunol"},{"issue":"5","key":"3867_CR48","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1172\/JCI116862","volume":"92","author":"M Svenson","year":"1993","unstructured":"Svenson M, Hansen MB, Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest. 1993;92(5):2533\u20139.","journal-title":"J Clin Invest"},{"issue":"1","key":"3867_CR49","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/1043-4666(93)90026-2","volume":"5","author":"MB Hansen","year":"1993","unstructured":"Hansen MB, Svenson M, Diamant M, Bendtzen K. High-affinity IgG autoantibodies to IL-6 in sera of normal individuals are competitive inhibitors of IL-6 in vitro. Cytokine. 1993;5(1):72\u201380.","journal-title":"Cytokine"},{"issue":"2","key":"3867_CR50","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/iid3.109","volume":"4","author":"J Karner","year":"2016","unstructured":"Karner J, Pihlap M, Ranki A, Krohn K, Trebusak Podkrajsek K, Bratanic N, et al. IL-6-specific autoantibodies among APECED and thymoma patients. Immun Inflamm Dis. 2016;4(2):235\u201343.","journal-title":"Immun Inflamm Dis"},{"issue":"4","key":"3867_CR51","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1182\/blood.V85.4.917.bloodjournal854917","volume":"85","author":"FA Montero-Julian","year":"1995","unstructured":"Montero-Julian FA, Klein B, Gautherot E, Brailly H. Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies. Blood. 1995;85(4):917\u201324.","journal-title":"Blood"},{"issue":"1","key":"3867_CR52","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4049\/jimmunol.180.1.647","volume":"180","author":"A Puel","year":"2008","unstructured":"Puel A, Picard C, Lorrot M, Pons C, Chrabieh M, Lorenzo L, et al. Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J Immunol. 2008;180(1):647\u201354.","journal-title":"J Immunol"},{"issue":"6","key":"3867_CR53","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/annrheumdis-2012-202768","volume":"72","author":"T Nanki","year":"2013","unstructured":"Nanki T, Onoue I, Nagasaka K, Takayasu A, Ebisawa M, Hosoya T, et al. Suppression of elevations in serum C reactive protein levels by anti-IL-6 autoantibodies in two patients with severe bacterial infections. Ann Rheum Dis. 2013;72(6):1100\u20132.","journal-title":"Ann Rheum Dis"},{"key":"3867_CR54","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.3389\/fimmu.2019.02629","volume":"10","author":"M Bloomfield","year":"2019","unstructured":"Bloomfield M, Parackova Z, Cabelova T, Pospisilova I, Kabicek P, Houstkova H, et al. Anti-IL6 Autoantibodies in an Infant With CRP-Less Septic Shock. Front Immunol. 2019;10:2629.","journal-title":"Front Immunol"},{"issue":"8","key":"3867_CR55","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/art.1780350814","volume":"35","author":"H Takemura","year":"1992","unstructured":"Takemura H, Suzuki H, Yoshizaki K, Ogata A, Yuhara T, Akama T, et al. Anti-interleukin-6 autoantibodies in rheumatic diseases. Increased frequency in the sera of patients with systemic sclerosis. Arthritis Rheum. 1992;35(8):940\u20133.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"3867_CR56","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/nbt1097-997","volume":"15","author":"L Ciapponi","year":"1997","unstructured":"Ciapponi L, Maione D, Scoumanne A, Costa P, Hansen MB, Svenson M, et al. Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist. Nat Biotechnol. 1997;15(10):997\u20131001.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"3867_CR57","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/eji.200324338","volume":"34","author":"P Galle","year":"2004","unstructured":"Galle P, Hougs L, Barington T, Svenson M, Svejgaard A, Thomsen AR, et al. Knocking out IL-6 by vaccination. Eur J Immunol. 2004;34(1):291\u2013300.","journal-title":"Eur J Immunol"},{"key":"3867_CR58","doi-asserted-by":"publisher","first-page":"19549","DOI":"10.1038\/srep19549","volume":"6","author":"L Desallais","year":"2016","unstructured":"Desallais L, Bouchez C, Mouhsine H, Moreau G, Ratsimandresy R, Montes M, et al. Immunization against an IL-6 peptide induces anti-IL-6 antibodies and modulates the Delayed-Type Hypersensitivity reaction in cynomolgus monkeys. Sci Rep. 2016;6:19549.","journal-title":"Sci Rep"},{"issue":"13","key":"3867_CR59","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.intimp.2007.08.026","volume":"7","author":"P Galle","year":"2007","unstructured":"Galle P, Jensen L, Andersson C, Cuzzocrea S, Di Paola R, Nicoletti F, et al. Vaccination with IL-6 analogues induces autoantibodies to IL-6 and influences experimentally induced inflammation. Int Immunopharmacol. 2007;7(13):1704\u201313.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"3867_CR60","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/rheumatology\/ker152","volume":"50","author":"M Narazaki","year":"2011","unstructured":"Narazaki M, Hagihara K, Shima Y, Ogata A, Kishimoto T, Tanaka T. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford). 2011;50(7):1344\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"3867_CR61","doi-asserted-by":"crossref","unstructured":"Baumann Benvenuti F, Dudler J. Long-lasting improvement of refractory antisynthetase syndrome with tocilizumab: a report of two cases. RMD Open. 2023;9(4):e003599.","DOI":"10.1136\/rmdopen-2023-003599"},{"issue":"12","key":"3867_CR62","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/rheumatology\/kew296","volume":"55","author":"SM Murphy","year":"2016","unstructured":"Murphy SM, Lilleker JB, Helliwell P, Chinoy H. The successful use of tocilizumab as third-line biologic therapy in a case of refractory anti-synthetase syndrome. Rheumatology (Oxford). 2016;55(12):2277\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"3867_CR63","doi-asserted-by":"crossref","first-page":"1497168","DOI":"10.3389\/fped.2024.1497168","volume":"12","author":"L Qiu","year":"2024","unstructured":"Qiu L, Shao X, Ma L, Fan Z, Yu H. Successful tocilizumab treatment for rapidly progressive interstitial lung disease with anti-MDA5-positive juvenile dermatomyositis: a case report and literature review. Front Pediatr. 2024;12:1497168.","journal-title":"Front Pediatr"},{"key":"3867_CR64","doi-asserted-by":"crossref","first-page":"635654","DOI":"10.3389\/fphar.2021.635654","volume":"12","author":"S Li","year":"2021","unstructured":"Li S, Li W, Jiang W, He L, Peng Q, Wang G, et al. The Efficacy of Tocilizumab in the Treatment of Patients with Refractory Immune-Mediated Necrotizing Myopathies: An Open-Label Pilot Study. Front Pharmacol. 2021;12:635654.","journal-title":"Front Pharmacol"},{"issue":"11","key":"3867_CR65","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/acr2.11493","volume":"4","author":"CV Oddis","year":"2022","unstructured":"Oddis CV, Rockette HE, Zhu L, Koontz DC, Lacomis D, Venturupalli S, et al. Randomized Trial of Tocilizumab in the Treatment of Refractory Adult Polymyositis and Dermatomyositis. ACR Open Rheumatol. 2022;4(11):983\u201390.","journal-title":"ACR Open Rheumatol"},{"issue":"6","key":"3867_CR66","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.autrev.2015.01.015","volume":"14","author":"T Vincent","year":"2015","unstructured":"Vincent T, Plawecki M, Goulabchand R, Guilpain P, Eliaou JF. Emerging clinical phenotypes associated with anti-cytokine autoantibodies. Autoimmun Rev. 2015;14(6):528\u201335.","journal-title":"Autoimmun Rev"},{"issue":"6","key":"3867_CR67","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.jaip.2023.04.002","volume":"11","author":"J Bayry","year":"2023","unstructured":"Bayry J, Ahmed EA, Toscano-Rivero D, Vonniessen N, Genest G, Cohen CG, et al. Intravenous Immunoglobulin: Mechanism of Action in Autoimmune and Inflammatory Conditions. J Allergy Clin Immunol Pract. 2023;11(6):1688\u201397.","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-026-03867-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03867-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03867-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:20:07Z","timestamp":1792066807000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-026-03867-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3867"],"URL":"https:\/\/doi.org\/10.1186\/s13075-026-03867-x","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the National Medical Ethics Committee of the Republic of Slovenia (approval number 0120\u2009\u2212\u2009118\/2023\/6). All participants gave written informed consent prior to inclusion in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No individual person\u2019s data were used in this study.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"182"}}